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Effect of angiotensin II and norepinephrine on early growth response
genes in the rat kidney. Angiotensin II (Ang II) has growth promoting
effects in a number of cells and tissues in vitro. The purpose of this
study was to examine the in vivo effect of Ang lion the renal expression
of the early growth response genes c-los, Egr-1 and c-jun. Adult male
rats underwent two basal 30 minute clearance periods during which the
normal saline vehicle was infused into the left renal artery. Normal
saline, Ang 11(50 ng/kg/min), or Ang II plus the Ang II antagonist Sar'
G1y8-angiotensin 11(10 tg/kg/min) were then selectively infused into the
left renal artery for two additional 30 minute periods. MAP was similar
during basal and Ang II infusion. Hemodynamic effects (decrease in
GFR and RPF and increase in renal vascular resistance) were observed
only in the Ang Il-infused left kidney allowing the right kidney to serve
as a paired control for the effects of anesthesia and surgery. Significant
increases in the expression of the early growth response genes Egr-1
and c-los, but not c-jun, were found in the Ang Il-infused left kidney
compared to the control right kidney. The simultaneous infusion of Ang
11(50 ng/kg/min) and the Ang II antagonist Sar1 Gly8-angiotensin 11(10
pg/kg/mm) blocked the increase in Egr-1 and c-los expression, demon-
strating the specificity of the response to Ang II. To compare the effect
of another renal vasoconstrictor on the expression of early growth
response genes, norepinephrine (40 nglkg/mmn) was infused into the left
renal artery. This dose lacked a systemic pressor effect, produced
vasoconstriction in the infused left kidney, but did not alter hemody-
namics of the right kidney. Norepinephrine significantly increased
Egr-1 and c-los and c-jun mRNA. In conclusion, intrarenal infusion of
Ang II and norepinephrine induced early growth response genes in the
kidney, an effect associated with cellular growth in other tissues. The
similarity of the response to two different vasoconstrictors raises the
possibility that early growth responses may be transduced, in part, from
renal hemodynamic effects.
Angiotensin II has growth-promoting effects in a number of
cells and tissues including vascular smooth muscle, endothe-
hum, adrenal cortex, heart, and kidney [1—9]. Application of a
growth stimulus to quiescent cells induces a number of early
growth response genes [10, 11]. This family of genes includes
the proto-oncogenes c-fos, c-fun, and the more recently de-
scribed early growth response gene-l (Egr-1). The protein
products of these genes are involved in transcriptional control
and lead to a cascade of gene activation which is thought to
mediate the growth response. Angiotensin II increases the
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expression of several growth-related genes in vitro including the
proto-oncogenes c-fos and c-myc, and the growth factors
TGF-f3 (which has inhibitory growth effects) and the A chain of
platelet derived growth factor [12—15]. As an initial step in
exploring the in vivo role of angiotensin II in renal growth, we
examined the expression of the early growth response genes
Egr-1, c-fos, and c-jun following angiotensin II infusion. As a
comparison vasoconstrictor, we also examined the effect of an
intrarenal infusion of norepinephrine on early growth response
gene expression.
Methods
The experimental design is outlined in Figure 1. Unilateral
infusions of vasoconstrictors into the left renal artery with
isolated ipsilateral physiologic actions allowed the right kidney
to serve as a paired control for the effects of anesthesia and
surgical manipulation. In the first series of experiments renal
hemodynamic responses to the intrarenal infusions were mea-
sured to establish the model used in the second series of
experiments examining gene expression.
Renal clearance studies
Male Sprague-Dawley rats weighing 250 to 275 g were anes-
thetized with mactin (100 mg/kg body wt administered by i.p.
injection; BYK Gulden, Konstanz, Germany) and placed on a
temperature-regulated table. A PE-50 polyethylene catheter
was inserted into the left femoral artery for blood sampling and
blood pressure monitoring by a pressure transducer (model P23
Db, Statham Instruments, Oxnard, California, USA) connected
to a duograph recorder (model 1CT-2H Gilson Medical Elec-
tronics, Middleton, Wisconsin, USA). The trachea was cathe-
terized with PE-240 tubing and the left external jugular vein was
catheterized with PE-50 for infusion. For the clearance studies
both ureters were catheterized with PE-lO and urine was
collected under mineral oil in pre-weighed vials. To determine
glomerular filtration rate (GFR) and renal plasma flow (RPF) a
solution of normal saline containing (methoxy 3H) inuhin (10
pCi/mi) and p-amino-hippurate (PAH, 10 mg/mi; Merck Sharpe
and Dohme, West Point, Pennsylvania, USA) was infused at a
rate of 1.2 mi/hr after a priming dose of 0.5 ml over five minutes.
After allowing 30 minutes for equilibration, two thirty minute
clearance collections were performed during which normal
saline was infused at a rate of 0.5 mllhr into the left renal artery
via a 33 gauge needle (Hamilton Company, Reno, Nevada,
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Design
Surgical Prep Period 1I::::::::::::1:::::::::::lPeriod2 l:::::::J
USA). Measurements made during these two periods were
averaged and termed Period 1. The position of the left renal
artery needle was confirmed by injection of a dilute solution
(1:100) of lissamine green. Following these baseline measure-
ments the left renal artery infusion of normal saline was either
continued (N = 4, time control) or was switched to angiotensin
11(50 ngfkg/min, N = 4) or norepinephrine (40 ng/kglmin, N =
7), and two thirty minute clearance periods were then per-
formed, the average of which was called Period 2. To replace
surgical losses and to maintain constancy of initial hematocrit,
all animals were infused with isooncotic rat plasma as follows:
1% of body weight was administered over 20 minutes prior to
the first measurements and an infusion rate of 0.5 mI/hr was
maintained throughout the study. Radioactivity in the urine and
plasma were determined by liquid scintillation counting. PAH
concentration in urine and plasma was determined colorimetri-
cally.
Gene expression studies
The second series of experiments were designed to examine
the expression of early growth response genes following the
intrarenal infusions. The experimental design was as outlined
above except GFR and RPF were not measured; therefore,
inulin and PAH were not included in the infusates and no
ureteral catheters were placed. The volume of the intravenous
infusions were identical between the two series of experiments.
As shown in Figure 1, normal saline vehicle was infused during
Period tin all animals followed by either continuation of normal
saline (N = 7), or a switch to angiotensin 11(50 ng/kg/min, N =
7), angiotensin 11(50 ng/kglmin) plus the angiotensin II antag-
onist Sar1 Gly8-angiotensin II (10 pg/kg/min, N = 7), or
norepinephrine (40 ng/kg/min, N = 7). At the end of the
experiment both kidneys were harvested and snap frozen for
subsequent RNA extraction.
Fig. 1. The experimental design is outlined
which involved selective infusions into the left
renal artery. During Period 1 the normal
saline vehicle was infused. During Period 2
the vehicle was either continued or replaced
by infusion of either Ang II alone (50 ng/kg/
mm), Ang 11(50 ng/kg/min) plus the Ang II
antagonist Sar' G1y8-angiotensin 11(10 g/kg/
mm), or norepinephnne (40 nglkg/min).
Northern hybridization
Total kidney RNA was isolated using minor modifications of
the guanidinium-isothiocyanate/cesium chloride method de-
scribed by Chirgwin and colleagues [16]. The RNA was dis-
solved in sterile water and RNA concentrations determined by
absorbance readings at 260 nm. Aliquots (20 g) of total RNA
were separated by electrophoresis in a 1% agarose gel contain-
ing 20 mM MOPS, 1 ms EDTA, 5 miss sodium acetate pH 7.0,
and 2.2 M formaldehyde, and transferred to nylon membranes
(Duralon UVTM Stratagene, La Jolla, California, USA). In each
gel equivalent loading of RNA, absence of degradation, and the
position of the 28S and 18S ribosomal RNA was determined by
ethidium bromide staining. An RNA ladder (BRL, Gaithers-
burg, Maryland, USA) was run in each gel to size the hybrid-
ized mRNA. RNA was fixed to the nylon membrane by
ultraviolet crosslinking (Stratalinker°M, Stratagene, California,
USA). The membranes were prehybridized at 60°C for four
hours in a buffer containing 5 x SSC, 5 x Denhardt's reagent, 50
mM Tris-hydrochioride, pH 7.5, 0.1% sodium pyrophosphate,
0.2% SDS, 200 pgIml sonicated, denatured salmon testes DNA,
and 100 j.tg/ml yeast tRNA. The membranes were then hybrid-
ized at 42°C with a random oligomer-primer labeled DNA
probes (see below) for 16 to 18 hours in a buffer containing 50%
deionized formamide, 5x SSC, lx Denhardt's reagent, 50mM
Tris-hydrochloride, pH 7.5, 0.1% sodium pyrophosphate, 1%
SDS, 100 jsg/ml salmon testes DNA, and 100 sg/ml yeast
tRNA. The membranes were washed for 45 minutes in 2x SSC
and 0.1% SDS twice at room temperature and once at 60°C, and
were then washed in 0.2x SSC and 0.1% SDS at 60°C for 45
minutes. Autoradiographs (Kodak XAR-5 film) were obtained
and quantified by computer assisted videodensitometry [17].
Duplicate northern blots were hybridized with c-fos and Egr-1
probes and the same blots were rehybridized with c-jun and
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Table 1. Renal hemodynamics during the time control experiment
Period 1 Period 2
MAPmmHg 117±3 119±4
GFR mI/mm
Right kidney 1.74 0.10 1.69 0.09
Left kidney 1.58 0.17 1.61 0.12
RPF mi/mm
Right kidney 4.62 0.46 4.48 0.50
Left kidney 4.55 0.15 4,25 0.20
RVRmm Hg minim!
Right kidney 13.26 0.90 14.05 1.05
Left kidney 13.42 0.41 14.74 0.88
Values are mean SEM. The normal saline vehicle was infused into
the left renal artery during both Period 1 and Period 2. No statistical
differences were seen.
actin after allowing sufficient time for the initial radioactivity to
decay.
DNA probes
The following DNA probes were used: early growth response
gene-i (Egr-1, gift of Vikas Sukhatme) [18], c-fos [19], c-jun
(gift of Daniel Nathans) [20] and actin [21]. For preparation of
the probes, we utilized the method of random oligomer-primer
labeling (Promega, Madison, Wisconsin, USA) with 32P-dCTP
(6000 Ci/mmol; NEN Dupont, Wilmington, Delaware, USA).
The specific activity of the probe was i —2 X lO9 cpm/g DNA.
Statistical analysis
All data are reported as mean SEM. The densitometry data
for Egr-1, c-los and c-jun mRNA have been normalized to the
actin signal. Statistical differences between Period 1 and Period
2 were analyzed by the Student's paired t-test or Wilcoxon
signed rank test depending on whether the values were nor-
mally distributed or not. A statistical significant difference
between values was considered for a P < 0.05.
Results
Renal clearance studies
The results of the time control experiment during which the
normal saline vehicle was infused during both Period i and
Period 2 are displayed in Table i. Mean arterial pressure
(MAP), GFR, RPF and renal vascular resistance (RVR) re-
mained stable in both the infused left kidney and the uninfused
right kidney throughout the study demonstrating the stability of
the preparation. The effect of a left renal artery infusion of
angiotensin II at a dose of 50 nglkg/min during experimental
Period 2 is displayed in Table 2. When angiotensin II was
substituted for vehicle during Period 2, a significant decrease in
GFR and RPF, and an increase in RVR was seen in the Ang
Il-infused left kidney. In contrast no significant changes in these
parameters occurred in the uninfused right kidney. Infusion of
norepinephrine (40 ngikg/min) into the left renal artery resulted
in a decrease in GFR and RPF which did not reach statistical
significance, and a significant increase in RVR (Table 3).
Smaller doses of norepinephrine had no measurable renal
hemodynamic effects, whereas larger doses resulted in a sys-
temic pressor effect (data not shown). The stability of GFR and
RPF in the uninfused right kidney combined with a lack of
Table 2. Renal hemodynamic effects of Ang II infusion into the left
renal artery
Period 1 Period 2
MAP mmHg 113 117
GFR mI/mm
Right kidney 1.73 0.10 1.62 0.19
Left kidney 1.70 0.25 1.26 0.32a
RPF mi/mm
Right kidney 4.79 0.32 4.61 0.35
Left kidney 4.62 0.37 3.58 0.88a
RVR mm Hg minim!
Right kidney 12.33 0.90 13.84 0.98
Left kidney 12.81 1.04 18.80 3.l3a
Values are mean SEM. The normal saline vehicle was infused into
the left renal artery during Period I and Ang 11(50 ngikg/min) was
infused into the left renal artery during Period 2.
a p < 0.05 vs. Period 1.
Table 3. Renal hemodynamic effects of norepinephrine infusion into
the left renal artery
Period 1 Period 2
MAP mmHg 125±4 129±4
GFR mi/mm
Right kidney 1.63 0.08 1.88 0.17
Left kidney 1.62 0.21 1.36 0.12
RPF mi/mm
Right kidney 4.15 0.21 4.66 0.50
Left kidney 4.21 0.40 3.46 0.36
RVRmm Hg mm/mi
Right kidney 13.82 1.22 15.31 1.61
Left kidney 16.62 2.39 20.46 2.03a
Values are mean SEM. The normal saline vehicle was infused into
the left renal artery during Period 1 and norepinephrine (40 ng/kg/min)
was infused into the left renal artery during Period 2.
a P <0.05 vs. Period 1.
change in mean arterial pressure provide evidence for a selec-
tive hemodynamic effect of Ang II and norepinephrine on the
left kidney and thus, provide a model in which the effects of
these vasoactive compounds on renal gene expression can be
studied in vivo using the uninfused right kidney as a paired
control.
Gene expression studies
The results of these studies are displayed in Table 4. The
effect of angiotensin II on Egr-1 mRNA is shown in Figure 2. In
all seven rats, an increase in Egr-1 mRNA was found in the Ang
TI-infused left kidney compared to the control right kidney with
the mean values in the 2 groups being 100 24 versus 152 30
O.D. units, respectively (P < 0.03). As can be seen, fairly
marked inter-animal variability was seen emphasizing the im-
portance of the paired analysis used in this study. The effect of
angiotensin II on c-fos mRNA is displayed in Figure 3. As was
seen for Egr-1, c-fos mRNA was consistently higher in the Ang
IT-infused left kidney compared to the control right kidney in all
seven rats with the mean values being 85 30 versus 121 38
O.D. units, respectively (P < 0.04). Thus, selective infusion of
angiotensin II into the left renal artery was associated with
increased expression of both Egr-1 and c-los mRNA. In con-
trast to the consistent increase in Egr-1 and c-fos, no significant
change was seen in c-jun mRNA (Ang IT-infused left kidney:
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Table 4. Effect of experimental maneuvers on Egr-1, c-fos, and c-jun
mRNA
Egr-1
mRNA
c-fos
mRNA
c-jun
mRNA
Time control
Right kidney (control)
Left kidney (NS)
231 77
208 73
129 34
95 25
743 275
659 191
Sar-Gly — Ang II
Right kidney (control)
Left kidney (Sar-Gly Ang
II)
307 136
284 100
102 33
83 23
756 60
926 128
Ang II
Right kidney (control)
Left kidney (Ang II)
100 24
152 308
85 30
121 388
632 136
732 111
Norepinephrine
Right kidney (control)
Left kidney
(norepinephrine)
920 185
9979 4576k
134 108
1017 8558
251 40
354 54
Values are mean SEM optical density units (actin-corrected). N =
7 each group. Abbreviations are: NS, normal saline; Sar-Gly Ang II,
Sar1 Gly8-angiotensin 11(10 jsg/kglmin); Ang II, angiotensin 11(50
ng/kg/min); norepi, norepinephrine (40 ng/kg/min).
a p < 0.05 vs. right (control) kidney.
632 136 vs. control right kidney: 732 111 O.D. units; P =
NS; Table 4).
To determine the specificity of the gene response to angio-
tensin II, Egr-1, c-fos, and c-jun mRNA were quantitated
following simultaneous infusion of Ang II, at a similar dose of
50 ng/kglmin, and the Ang II antagonist Sar1 G1y8-angiotensin
II, at a dose of 10 tgIkgImin into the left renal artery. In
contrast to the increased expression of Egr-1 and c-los detected
previously with just Ang II infusion, no significant change in
either Egr-1 mRNA (control right kidney: 307 136 vs. infused
left kidney: 284 100 O.D. units; P = NS) or c-fos mRNA
(control right kidney: 102 33 vs. infused left kidney: 83 23
O.D. units; P = NS), was seen during the combined infusion of
Ang II and its antagonist providing evidence for the specificity
of the response to Ang II. No significant change in c-jun mRNA
was seen during the combined infusion (Table 4). As a further
control the expression of Egr-1, c-los, and c-jun mRNA was
examined in both kidneys of a separate group of seven rats
following infusion of the normal saline vehicle into the left renal
artery during both Period 1 and Period 2. This experiment was
performed to exclude a change in expression of these genes
secondary to non-specific manipulation of the left renal artery.
As can be seen in Table 4, no change in Egr-1 (control right
kidney: 231 77 vs. infused left kidney: 208 73 O.D. units;
P = NS), c-los mRNA (control right kidney: 129 34 vs.
infused left kidney: 95 25 O.D. units; P = NS), or c-jun
mRNA (control right kidney: 743 275 vs. infused left kidney:
659 191 O.D. units; P = NS) was detected following saline
infusion further supporting the specificity of the previously
noted changes in response to Ang II.
Although Ang II has direct growth promoting action on
proximal tubular epithelium in vitro [8], we questioned whether
the vasoconstrictive actions in vivo may play a role in the
stimulation of early growth response genes and therefore ex-
amined the effects of another renal vasoconstrictor agent,
norepinephrine. As shown in Table 4, a significant increase in
Egr-1 mRNA (control right kidney: 920 185 vs. infused left
kidney: 9979 4576 O.D. units; P < 0.02) c-fos mRNA (control
right kidney: 134 108 vs. infused left kidney: 1017 855 O.D.
units; P < 0.02), and c-jun mRNA (control right kidney: 251
40 vs. infused left kidney: 354 54 O.D. units; P = NS) was
seen in the norepinephnne infused left kidney compared to the
uninfused right kidney.
Discussion
Intrarenal infusion of Ang II at the dose used in this study
decreased GFR and RPF, and increased RVR only in the
infused left kidney and had no effect on systemic pressure,
presumably due to the efficient extraction by the infused
kidney, thus providing a model in which the effects of Ang II on
renal gene expression could be studied in vivo using the
uninfused right kidney as a paired control [22]. Using this
model, significant and consistent increases in the expression of
the early growth response genes Egr-1 and c-los but not c-jun
were found in the Ang Il-infused left kidney compared to the
control right kidney. Based on the infusion rate of 50 ng/kglmin
and a mean renal plasma flow during Ang II infusion of 3.58
mi/mm (Table 2), we estimate the local concentration of Ang II
in plasma perfusing the left kidney at between 108 to iO M,
a concentration associated with renal growth effects in vitro [8].
The specificity of this response was verified both by the
simultaneous infusion of Ang II and the Ang II antagonist
Sar-Gly Ang II, which blocked the increase in Egr-1 and c-los
expression, and by the lack of change in the expression of these
genes in the time control experiment despite manipulation of,
and infusion of the normal saline vehicle into the left renal
artery.
Evidence for the growth promoting effects of Ang II is
abundant but largely derived from cell culture systems in vitro.
Ang II is a mitogen for cultured endothelial and adrenocortical
cells [5, 23]. Hypertrophic and/or hyperplastic growth of cul-
tured rat and human vascular smooth muscle cells can be
induced by Ang II [1, 2]. This response in vascular smooth
muscle is independent of intracellular alkalinization or activa-
tion of Na/H exchange, but dependent upon mobilization of
intracellular Ca and protein kinase C activation [13, 15]. In
vivo blockade of Ang II formation by a converting enzyme
inhibitor (CEI) reduces the vascular smooth muscle hypertro-
phy that occurs in SHR rats, and blunts the myointimal prolif-
erative response following vascular injury, effects independent
of the antihypertensive action of these drugs as similar reduc-
tions in BP by other agents have minimal effect [3, 24]. In
cultured cardiac myocytes, Ang II increases total protein and
protein synthesis, an effect blocked by Ang II antagonism [6].
Also, independent of blood pressure reduction, CEI therapy
has been shown to decrease the cardiac hypertrophy of chronic
hypertension and aortic banding [71. These growth effects of
Ang II may be modified through the interactions with other
growth factors including PDGF, TGF-/3, and epidermal growth
factor [12, 14, 25—271.
Since the kidney is composed of a variety of cell types, and
total kidney RNA was examined in the current study, the cell or
cells responsible for the observed changes in early growth
response gene expression remain to be determined. The clear-
est renal growth promoting effects of Ang II are those noted in
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proximal tubular cells where Ang 11(10—8 M) induced hypertro-
phy of these cells [8]. Of note, this hypertrophy was associated
with increased expression of the proto-oncogenes c-fos, c-myc,
and c-N-ras. The mesangial cell is another candidate target cell
as Ang II induced increased 3H-thymidine incorporation and
cell number in cultured mesangial cells, particularly fetal cells
[28, 29]. Vascular smooth muscle cells could also be the target
cell for Ang II. In vitro, Ang Il-induced hypertrophy of these
cells is associated with increased expression of early growth
response genes [13, 15]. If a cell of relatively low abundance,
such as the mesangial or smooth muscle cell, was responsible
for the changes in early growth response gene expression
observed in our study, then the magnitude of the response may
have been diluted by the presence of RNA from other non-
responding cell types since our results are expressed in the
conventional fashion as a proportion of total kidney RNA.
The mechanism of the observed changes in Ang Il-induced
gene expression could be due to direct effects of Ang II on
responding cells, secondary to Ang Il-induced hemodynamic
changes, or both. The ability of Ang II to induce growth and
early growth response gene expression in vitro in vascular
smooth muscle and renal tubular cells clearly demonstrates that
Ang II does have direct growth promoting effects. However,
mechanical factors can also activate early growth response
genes and potentially play a role in growth and tissue remodel-
ing. For example the c-fos and c-myc proto-oncogenes are
LI
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Right kidney Left kidney
(control) (Ang II)
Fig. 2. The effect of a left intrarenal infusion of Ang II (50 ng/kg/min) on Egr-1 mRNA is displayed in this figure. The autoradiograph of the
Northern blot hybridized with an Egr-1 cDNA probe is in the upper portion of the figure and a graphic display of the densitometry results
(actin-corrected) is in the lower portion of the figure. The control right kidney is designated by "C" and the Ang Il-infused left kidney by "Ang
II". Each pair of lanes represents a separate rat (N = 7). < 0.05 vs. control.
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Fig. 3. The effect of a left intrarenal infusion of Aug II (50 ng/kglmin) on c-fos mRNA is displayed in this figure. The autoradiograph of the
Northern blot hybridized with a c-fos DNA probe is in the upper portion of the figure and a graphic display of the densitometry results
(actin-corrected) is in the lower portion of the figure. The control right kidney is designated by "C" and the Ang 11-infused left kidney by "Ang
II". Each pair of lanes represents a separate rat (N = 7). *P < 0.05 vs. control.
induced in ventricular myocardium within one hour of applying
a pressure load [30]. Similarly, elevated pressure within the
pulmonary circulation is associated with increased expression
of the B chain of PDGF [31]. Stretching cultured cardiac cells
stimulated c-fos expression in a stretch dependent fashion [32].
The induction of Egr-1, c-fos, and c-jun mRNA by norepineph-
rifle, another renal vasoconstrictor, suggests renal hemodynam-
ics changes may play a primary role in the Ang Il-induced
increase in these early growth response genes. This potential
link between renal vasoconstriction and growth would be
strengthened if the same cell types were involved in the
induction of these growth genes and if the response was
generalized to other vasoconstrictor agents. Another mecha-
nism by which Ang II may exert growth effects within the
kidney is by its ability to stimulate ammoniagenesis in renal
tubular cells, ammonia being a stimulus to renal tubular hyper-
trophy [33, 34]. Thus, the changes in early growth response
gene expression seen with intrarenal Ang II infusion could be
due to both direct and indirect effects of Ang II.
While studies of cultured renal and non-renal cells have
provided evidence for growth promoting effects of Ang II,
support for such an action of Ang II on renal growth in vivo is
modest. Fogo et al reported that converting enzyme inhibition
retarded maturational growth of glomeruli [35]. However, cer-
tain states associated with elevated renin secretion clearly do
not display associated renal growth. For example, dietary salt
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restriction and unilateral renal artery stenosis actually lead to
lower renal size despite heightened activity of the renin angio-
tensin system, chronic infusion of Ang II does not result in renal
or glomerular growth, and Ang II inhibition does not affect the
compensatory hypertrophy which occurs following uninephrec-
tomy or dietary protein-induced growth [36—38]. The lack of a
consistent association between activation of the renin angioten-
sin system and renal growth points to the likelihood that
additional yet unidentified factors, including perhaps hemody-
namic ones, are likely to modulate the growth inducing effects
of Ang II in vivo. The present studies do, however, suggest that
the earliest steps in Ang Il-induced renal growth can occur in
vivo, even in a normal animal, and may be related to renal
hemodynamic changes.
Genes that are induced early and transiently in response to a
growth stimulus and whose induction does not require prior
protein synthesis are termed early growth response or immedi-
ate-early response genes [10, 11]. The protein products of some
of these genes including c-fos, c-jun and Egr-1, have a nuclear
location and act as transcriptional factors that induce a cascade
of gene activation thought to mediate the growth response.
Besides proliferative stimuli these genes can be induced by
hypertrophic stimuli, and may also play a role in cellular
differentiation and neuronal excitation [11, 39, 40]. In the
kidney induction of early growth response genes occurs early in
the proliferative phase following nephrotoxic or ischemia!reper-
fusion injury, following unilateral nephrectomy (although this
has not been a universal finding), and in polycystic kidneys
[41—43]. During Ang Il-induced hypertrophy of vascular smooth
muscle, one of the earliest responses is induction of c-fos
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(Control) (Ang II)
Fig. 4. The effect of a left intrarenal infusion of Ang II (50 ng/kg/min) on c-jun mRNA is displayed in this figure. The autoradiograph of the
Northern blot hybridized with a c-jun cDNA probe is in the upper portion of the figure and a graphic display of the densitometry results
(actin-corrected) is in the lower portion of the figure. The control right kidney is designated by 'C" and the Ang lI-infused left kidney by "Ang
II". Each pair of lanes represents a separate rat (N = 7).
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mRNA [13, 15]. Similarly, increased renal proximal tubular cell
expression of c-fos was seen in vitro following exposure to Ang
II [8]. The baseline variation in the expression of these genes
emphasizes the importance of the paired analysis used in this
study. This variability may be related to differences in the
degree of activation of the renin-angiotensin system or to other
yet undefined factors related to anaesthesia and surgery. The
lack of an increase in c-jun signifies some degree of specificity
for the effects of Ang II on early growth response gene
expression in the kidney. Differences in induction kinetics are
not uncommon with this family of genes [11, 40]. The more
distal growth events which follow these early increases in Egr-1
and c-fos mRNA and their regulators remain to be defined.
In conclusion, angiotensin II specifically activates early
growth response genes in the kidney, an effect associated with
cellular growth in other tissues. The similar pattern of induction
of these genes by norepinephrine suggests a primary role for
renal hemodynamic changes in the growth responses of the
kidney.
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